Zota Health Care Investor Presentation: Q2FY27 Revenue Up 54.58% YoY to ₹19,933 Lakhs
Zota Health Care's Q2FY27 investor presentation highlights a 54.58% YoY revenue increase to ₹19,933 lakhs, driven by Davaindia sales and Everyday Herbal Group growth. EBITDA turned positive at ₹791.72 lakhs. The Davaindia network reached 2,840 stores, with plans to accelerate expansion in H2FY27.
The investor presentation provides comprehensive financial and operational updates, including significant revenue growth and positive EBITDA, which are material information for investors and analysts.
The company reported significant year-on-year revenue growth, positive EBITDA, and provided a positive outlook for future expansion, indicating strong performance and strategic progress.
Zota Health Care Limited has submitted an Investor Presentation detailing its performance for Q2FY27. The company reported a significant year-on-year increase in revenue from operations, which grew by 54.58% to ₹19,933.14 lakhs. This growth was primarily driven by a 76.25% YoY increase in Davaindia Sales and a 78.99% YoY growth in the Everyday Herbal Group.
EBITDA turned positive, reaching ₹791.72 lakhs, with an EBITDA margin of 3.97%, indicating a substantial sequential improvement in profitability. The company consciously moderated the pace of Davaindia store additions in Q2FY27 to consolidate the expanded network and focus on improving store-level productivity and cash generation. Despite this measured approach, the Davaindia network expanded to 2,840 stores, achieving quarterly customer footfalls of 66.17 lakhs and Gross Merchandise Value (GMV) of ₹18,791 lakhs.
Looking ahead, Zota Health Care plans to accelerate Davaindia network additions in H2FY27 while maintaining a strong focus on store-level productivity, operating efficiency, and cash generation. The company's strategic initiatives, including the acquisition of Everyday Herbal Group and Curexis, along with brand ambassador appointments, are expected to further strengthen its market position.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.